Inclusion Criteria:

- Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC

- Unresectable stage IIIA or IIIB disease; patients must be surgically staged to
confirm N2 or N3 disease; patients may have invasive mediastinal staging by
mediastinoscopy, mediastinotomy, EBUS-TBNA, EUS, or VATS within 30 days prior to
registration

- Patients with any T with N2 or N3 are eligible; patients with T3, N1-N3 disease are
eligible if deemed unresectable; patients with T4, any N are eligible

- Patients must have measurable disease, i.e., lesions that can be accurately measured
in at least 1 dimension (longest dimension in the plane of measurement is to be
recorded) with a minimum size of 10 mm by CT scan (CT scan slice thickness no greater
than 5 mm); tumor measurements must be taken within 42 days prior to registration

- Patients with a pleural effusion, which is a transudate, cytologically negative and
non-bloody, are eligible if the radiation oncologist feels the tumor can be
encompassed within a reasonable field of radiotherapy

- If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too
small to tap, the patient will be eligible; patients who develop a new pleural
effusion after thoracotomy or other invasive thoracic procedure will be eligible

- The institution's pre-enrollment biomarker screening at a CLIA certified lab
documents presence of known "sensitive" mutations in EGFR TK domain (exon 19
deletion, L858) and EML4-ALK fusion arrangement; either the primary tumor or the
metastatic lymph node tissue may be used for testing of mutations

- The institution's pre-enrollment biomarker screening at a CLIA certified lab
documents absence of T790M mutation in the EGFR TK domain

- Appropriate stage for protocol entry, including no distant metastases, based upon the
following minimum diagnostic workup:

- History/physical examination, including recording of pulse, blood pressure (BP),
weight, and body surface area, within 45 days prior to registration

- Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to
mid-thighs) within 30 days prior to registration; PET/CT must be negative for
distant metastasis

- CT scan of the chest with contrast (unless medically contraindicated) within 30
days prior to registration;

- Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with
contrast, if MRI medically contraindicated) within 30 days prior to registration

- Zubrod performance status 0-1 within 14 days prior to registration

- Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

- Platelets >= 100,000 cells/mm^3

- Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve
hemoglobin [Hgb] >= 8.0 g/dl is acceptable)

- Calculated creatinine clearance >= 50 ml/min (by Cockroft-Gault formula) within 14
days prior to registration

- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 X upper limit of
normal (ULN) within 14 days prior to registration

- Bilirubin < 3 X ULN within 14 days prior to registration

- Negative serum pregnancy test within 14 days prior to registration for women of
childbearing potential

- Patient must provide study specific informed consent prior to study entry, including
consent for mandatory screening of tissue

Exclusion Criteria:

- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
for a minimum of 730 days (2 years) (for example, carcinoma in situ of the breast,
oral cavity, or cervix are all permissible)

- Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
different cancer is allowable

- Prior radiotherapy to the region of the study cancer that would result in overlap of
radiation therapy fields

- Atelectasis of the entire lung

- Contralateral hilar node involvement

- Exudative, bloody, or cytologically malignant effusions

- Severe, active co-morbidity, defined as follows:

- Unstable angina and/or congestive heart failure requiring hospitalization within
the last 6 months

- Transmural myocardial infarction within the last 6 months

- Acute bacterial or fungal infection requiring intravenous antibiotics at the
time of registration

- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization or precluding study therapy at the time of
registration; hepatic insufficiency resulting in clinical jaundice and/or
coagulation defects; note, however, that laboratory tests for liver function and
coagulation parameters are not required for entry into this protocol

- Acquired immune deficiency syndrome (AIDS) based upon current Centers for
Disease and Control (CDC) definition; note, however, that human immunodeficiency
virus (HIV) testing is not required for entry into this protocol; the need to
exclude patients with AIDS from this protocol is necessary because the
treatments involved in this protocol may be significantly immunosuppressive;
protocol-specific requirements may also exclude immuno-compromised patients

- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception; this exclusion is
necessary because the treatment involved in this study may be significantly
teratogenic

- Prior allergic reaction to the study drug(s) involved in this protocol